Aldeyra Therapeutics Inc (ALDX) Quote

ALDX under $4

NOTICE TO LONG-TERM ALDEYRA THERAPEUTICS, INC. (NASDAQ: ALDX) INVESTORS

Grabar Law Office is investigating claims on behalf of Aldeyra Therapeutics, Inc. (NASDAQ: ALDX) shareholders. The investigation concerns whether certain officers of FMC have breached their fiduciary duties owed to the company.

Current Aldeyra shareholders who have continuously held Aldeyra shares since prior to January 7, 2021 should click here: https://grabarlaw.com/the-latest/aldeyra-sahreholder-investigation/. You can seek corporate reforms, the return of funds back to company coffers, and a court approved incentive award at no cost to you whatsoever.

Why: A recently filed securities fraud class action complaint alleges that Aldeyra Therapeutics, through certain of its officers and directors, made materially false and misleading statements regarding the Company's business, operations, and prospects. Specifically, it is alleged that the Company made false and misleading statements about or failed to disclose: (i) the ADX-2191 new drug application (“NDA”) did not include adequate and well-controlled investigations and thus failed to show substantial evidence of ADX-2191's effectiveness; (ii) as a result, the FDA was unlikely to approve the ADX-2191 NDA in its current form; (iii) accordingly, Aldeyra had overstated ADX-2191's clinical and/or commercial prospects; and (iv) as a result, Aldeyra’s public statements were materially false and misleading at all relevant times.

If you have continuously held Aldeyra shares since prior to January 7, 2021, you are encouraged to visit https://grabarlaw.com/the-latest/aldeyra-sahreholder-investigation/, contact Joshua H. Grabar at jgrabar @FH-6085.

Still progressing here. I think they have been prudent, of late... with the AbbVie option agreement for Reproxalap and other shots on goal without partners. There is certainly upside with continued clinical success. Any updated views on Aldeyra?

Early Barchart 100
https://www.barchart.com/stocks/performance/percent-change/advances?timeFrame=today&viewName=main&screener=overall&orderBy=percentChange&orderDir=desc

I added 3,500 shares on 10/16 as well below $1.80. I wish I leaned in more. I am a holder and still see long-term upside from here.

ALDX: Just crossed the (dangerous) 1.5-Hrs-Into-The-Open-Rubicon, and movin' UP from there!! (Not easy to do for ANY stock.)

Nice grab. It's good to be the early bird. I knew nothing about the company, just saw the news.

Me too, Dude. (And this Firm has worked on this drug for a long time; and that ain't NO 'small-potatoes' Company that just partnered with them either.)

Yep. I snatched up some of this pre-market.

ALDX: Could have a good day here; 'Dry Eye' syndrome afflicts MILLIONS worldwide!

I bought to average down today, it seems a sensible move.

With the pending readouts and relatively short trials that may provide additional support, I agree.

Also, the company has some breathing room with > $2 per share in cash after all liabilities as of 6/30 and only burning ~ $0.20 per share quarterly.

The current sub $2 share price looks attractive to me.

Ouch indeed, but it isn’t over for dry eye and we are expecting one other different P3 indication readout this year.

Ouch

A not so great day yesterday for $ALDX.

Small potential indication costing the 25% run up we have in expectation of H2 events.

It isn’t over for ADX-2191 yet though…

I have been invested here (smaller position than in AVXL) also. Binary/inflection points appear to be ahead mid-2023. We appear to have several shots on goal.

Yet another great day for aldeyra.

No one invested here?

Another great day for Aldeyra. In due course probably pay handsomely.

Good day for Aldeyra!

That’s biotech.

what I meant was the time line

mid 2022

Agree and believe that is what I just said.

yeah but heres the kicker

ALDX
Primary Endpoint of TRANQUILITY-2 Trial Modified to be Met if Either Ocular Redness or Schirmer Test Achieved; Target Enrollment Increased from 300 to up to 400 Patients; Top-Line Results Expected Mid-2022

So TRANQUILITY-2 endpoints to be changed to meet either Redness or Schirmer for potential approval.

Could be fine not least given that secondary p-value.

Still hope!

ALDX NEWS https://www.streetinsider.com/Business+Wire/Aldeyra+Therapeutics+Announces+Top-Line+Results+from+the+Phase+3+TRANQUILITY+Trial+in+Dry+Eye+Disease/19374659.html

Yeah not good.

NEWS HALT ))) 12/20/2021 16:00:34 ALDX Aldeyra Therapeutics Cmn Stk NASDAQ
T1

Looks like the market finally clicked that ocular redness is the primary endpoint over the conventional Schirmer’s test as agreed by the FDA trial protocol.

ADX-1612 and ADX-1615, Chaperome Inhibitors

Last summer I dove into the mechanism of action for ADX-1612 and spent a fair amount of time looking at HSP90 on PubMed. It is a widely recognized target. It will be interesting to see how the numerous assets at ALDX are managed. It's challenging to put a market cap and time to reach that value but they have great potential, no doubt. Current market conditions will probably make for a wild ride. Good Luck!

https://pubmed.ncbi.nlm.nih.gov/?term=hsp90+inhibitor

I agree, ALDX has great potential.

RASP-INHIBITION IN SYSTEMIC DISEASES

ADX-629 became a topic in the recent conference call so I did a revisit of that therapeutic. Glad I did since ADX-629 offers an impressive opportunity to further RASP inhibition. Several nuggets to pass along from a quick review of ADX-629:

The clinical trial NCT04847544 for Treatment of COVID-19 was initiated in April. It is recruiting N=30 and estimated completion this year.

https://clinicaltrials.gov/ct2/show/NCT04847544?term=aldeyra&recrs=abdf&draw=2&rank=1

Secondly, the phase 1 results showed target engagement "Also Improved Lipid Profiles". Lipid therapeutics have a large market, i.e., cardiovascular disease. Look at slide #17.

https://ir.aldeyra.com/static-files/33742ce3-ebdc-4569-9f65-b5b7bd8c73eb

The asthma trial is also on the trial list.

https://clinicaltrials.gov/ct2/results?term=aldeyra&recrs=b&recrs=a&recrs=f&recrs=d&age_v=&gndr=&type=&rslt=&Search=Apply%5D

Six ongoing clinical trials explains the recent raise in capital and great timing on that. Kudos to management!

Perceptive Advisors SEC form 4
3 May 2021 shows 1,200,000 shares bought at $12.50 = $15,000,000
They now have a total of 9.9 million shares which at $12.50 = $123,750,000. They have been adding since July 2020. Safe to say they have a positive outlook, eh?

It will stay above the $12.50 offer price just like last time especially given the great P3 trial readout.

I wouldn't touch this personally with a ten foot stick for a while not bashing but that's a heck of a lot of dilution coming out. 125 million dollars and able to add a lot more.

Bought in again @$12.89.

Huge $125,000,000 offering & can add another $18,750,000 million

Most def

Sold today avg $15.07. Figured they’d needmore funding and the price would dip waiting for a NDA filing and next P3 readout in H2.

Plenty time to buy back in cheaper, which should be a nice long term hold.

* * $ALDX Video Chart 04-27-2021 * *

Link to Video - click here to watch the technical chart video

Good volume. When it slows it'll fade hard imho Wish could get locates some where. 4x highest volume day ever

Billion dollars traded today so far

Yes, usually have something going on or at least some kind revenues from something. Not just spending money.

Looking GOOD

You seem surprised. Ever invested in pre-revenue biotechs?

Hmmm 0 profit, 0 revenus, debt, negative cash flow, with a $1.52 book value.

Profitability
Profit Margin 0.00%
Operating Margin (ttm) 0.00%

Management Effectiveness
Return on Assets (ttm) -27.28%
Return on Equity (ttm) -69.81%

Income Statement
Revenue (ttm) N/A
Revenue Per Share (ttm) N/A
Quarterly Revenue Growth (yoy) N/A
Gross Profit (ttm) N/A
EBITDA -34.61M
Net Income Avi to Common (ttm) -37.55M
Diluted EPS (ttm) -1.11
Quarterly Earnings Growth (yoy) N/A

Balance Sheet
Total Cash Per Share (mrq) 1.12
Total Debt (mrq) 15.33M
Total Debt/Equity (mrq) 25.76
Current Ratio (mrq) 6.69
Book Value Per Share (mrq) 1.54

Cash Flow Statement
Operating Cash Flow (ttm) -37.49M
Levered Free Cash Flow (ttm) -20.28M

ALDX $15.30 +37%

ALDX $14.50 +30%

This article supports the narrative that ALDX provides, namely, the current products for dry eye take a long time to have any effect and hard to keep people from discontinuing use.

https://www.ajmc.com/view/evolving-knowledge-of-the-unmet-needs-in-dry-eye-disease

The close on Friday, 3/19/2021
I watched the market on Fidelity Active Trader Pro and ALDX was at ~500,000 shares at 3:40 today and hit 1,000,000 by 3:58. When I looked at it after the close, 4,200,000 so in the last minute or two, 3 million shares at $12/share or $36 million. What's up with that? Somebody wanted 3 million shares without moving the price? How can that volume be executed in a minute or two? I could believe 50 - 100 k shares but 3 million? An issue with Fidelity showing volume? Please enlighten me.

ALDX $14.45 looks very good now. Strong breakout setting for next big upward move